The Role of Nuclear Medicine in Imaging and Therapy of Prostate Cancer : The State of the Art - 12/11/24
Résumé |
Prostate cancer (PCa) is the second most diagnosed cancer in men. In recent years, nuclear medicine has played an expanding role in diagnosing, staging, monitoring, and treating PCa. Specifically, the introduction of prostate-specific membrane antigen PET/computed tomography has significantly contributed to detecting locoregional and distant disease. Radioligand therapy, with its capacity to induce highly selective cytotoxic effects, is progressively being integrated into PCa therapy. The advent of novel therapeutic agents, additional indications, and a more comprehensive integration between nuclear imaging and therapy, represent the forefront of nuclear medicine in PCa.
Le texte complet de cet article est disponible en PDF.Keywords : Prostate cancer, Prostate-specific membrane antigen, PET, Theranostics, Radioligand therapy, Nuclear medicine
Plan
Vol 52 - N° 1
P. 13-24 - février 2025 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?